Clinical DevelopmentLast reviewed April 2026

No Observed Adverse Effect Level(NOAEL)

The highest dose in a toxicology study that does not produce a statistically or biologically significant adverse effect compared to controls.

Usage Examples

The 28-day rat tox study identified NOAEL at 30 mg/kg/day based on histopathology and clinical chemistry.
Human equivalent dose calculation from the NOAEL supported the 0.5 mg/kg FIH starting dose.

What is NOAEL?

NOAEL is the cornerstone output of nonclinical toxicology studies — the highest tested dose producing no biologically meaningful adverse effect. It drives first-in-human starting dose calculations per FDA's 2005 guidance: human equivalent dose (HED) is derived from the NOAEL by allometric scaling (typically body surface area), then reduced by a safety factor (commonly 10x) to estimate the Maximum Recommended Starting Dose (MRSD) for Phase 1.

For small molecules, NOAEL-based dose selection is the default. For high-risk biologics with novel mechanisms, MABEL-based dosing is preferred because biologic pharmacology can produce clinically meaningful effects at doses well below NOAEL (e.g., TGN1412). NOAEL identification requires careful toxicology study design with graded dose levels, comprehensive endpoints, and statistical interpretation. Disagreements about what constitutes a "biologically meaningful" effect are common during IND review.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ICH M3, FDA GUIDANCE FIRST IN HUMAN DOSE, ICH S7A.

FDAEMAPMDA

When This Matters

The 28-day rat tox study identified NOAEL at 30 mg/kg/day based on histopathology and clinical chemistry.
Human equivalent dose calculation from the NOAEL supported the 0.5 mg/kg FIH starting dose.

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

ICH M3FDA GUIDANCE FIRST IN HUMAN DOSEICH S7A

Frequently Asked Questions

Biologically meaningful changes suggesting toxicity: statistically significant differences from control AND biological plausibility as toxicity. Small statistical fluctuations without biological relevance don't define the NOAEL. Expert toxicology judgment is required — FDA reviewers often negotiate this determination.

Allometric scaling from animal to human (typically body surface area, sometimes body weight for biologics), yielding the Human Equivalent Dose (HED). A safety factor (standard 10x) is applied to derive the Maximum Recommended Starting Dose (MRSD). Further adjustments may apply based on mechanism and indication.

For biologics with novel mechanisms that could produce clinically meaningful effects at doses below NOAEL — especially immunomodulators, agonists targeting pharmacologic amplification cascades, and products with species-specific pharmacology. The TGN1412 incident (2006) established MABEL as the default for this product class.